secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2025-08-25T23:59:59+00:00
Accession:  0001193125-25-187733
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst settles Lupin patent litigation; generic FIRDAPSE launch no earlier than Feb 2035
--------------------------------------------------------------------------------

- Lupin granted license to market generic FIRDAPSE beginning February 25, 2035, if FDA-approved.
- All ongoing patent litigation between Catalyst/SERB and Lupin in New Jersey terminated.
- Prior settlements with Teva and Inventia for FIRDAPSE generics already in place.
- Pending patent litigation against Hetero for FIRDAPSE's Orange Book-listed patents continues.
- Settlement will be submitted to FTC and DOJ for review as required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525187733/0001193125-25-187733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525187733/d915025d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-187733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer